Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

248
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
248
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

160
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
160
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

225
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
225
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

225
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
225
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetic-Pharmacodynamic Model for Secukinumab in Psoriasis Patients.

The Journal of investigative dermatology·2026
Same author

Use of hollow fiber systems to model treatment of infections: A practical guide.

iScience·2026
Same author

Pharmacokinetic-pharmacodynamic modeling using combined time-kill data for meropenem and colistin or polymyxin B combination effects in <i>Acinetobacter baumannii</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Current practices in the use and monitoring of intravenous unfractionated heparin infusions - A cross-sectional UK survey.

Thrombosis research·2026
Same author

Polymerase-inhibitor drug synergy and mutational signatures in different epithelial cell models of RSVA and hPIV3 infection.

npj antimicrobials and resistance·2026
Same author

Precision medicine in paediatrics: Progress and priorities.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Jan 11, 2026

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

813

From reactive to predictive: Advancing biologic dosing in dermatology.

Anke Eylenbosch1, Ruoheng Wei2, Rani Soenen1

  • 1Department of Head and Skin, Ghent University Hospital, Ghent, Belgium.

Journal of the European Academy of Dermatology and Venereology : JEADV
|November 14, 2025
PubMed
Summary

Model-informed precision dosing (MIPD) offers personalized biologic therapy for inflammatory skin diseases, improving outcomes by adjusting doses based on individual patient data. This approach optimizes treatment effectiveness and reduces side effects compared to standard regimens.

Keywords:
adalimumabbiological productsmodel‐informed precision dosingpsoriasistherapeutic drug monitoringustekinumab

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.8K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.1K

Related Experiment Videos

Last Updated: Jan 11, 2026

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

813
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.8K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.1K

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Biologic therapies are effective for chronic inflammatory dermatoses but standard dosing fails to account for individual variability.
  • This leads to suboptimal drug exposure, impacting treatment response and safety.
  • Current empirical dose adjustments lack data-driven justification.

Purpose of the Study:

  • To review limitations of current biologic dosing in dermatology.
  • To explore therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) for personalized treatment.

Main Methods:

  • Synthesizing evidence on TDM and MIPD for inflammatory dermatoses.
  • Examining dose-exposure-response relationships and pharmacokinetic/pharmacodynamic modeling.
  • Discussing patient-specific factors (pharmacogenomics, biomarkers) and digital health advancements.

Main Results:

  • TDM allows dose optimization based on drug levels but has predictive limitations.
  • MIPD integrates population models with patient data for adaptive dosing recommendations.
  • MIPD enables proactive adjustments, potentially improving outcomes and reducing overtreatment.

Conclusions:

  • MIPD represents a shift towards dynamic, patient-centric biologic therapy.
  • Combining monitoring, digital tools, and profiling can maximize response and minimize toxicity.
  • MIPD enhances the long-term sustainability of biologic treatments in dermatology.